Eidos Therapeutics Inc
(EIDX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2016 | |
| Assets | |
| Current Assets | |
| Cash & Cash Equivalents | 1,956 |
| Receivables | 5 |
| Other current assets | 7 |
| TOTAL | $1,968 |
| Non-Current Assets | |
| Other Non-Current Assets | 7 |
| TOTAL | $7 |
| Total Assets | $1,975 |
| Liabilities | |
| Current Liabilities | |
| Accounts payable and accrued liabilities | 90 |
| Accrued Expenses | 140 |
| Other current liabilities | 50 |
| TOTAL | $293 |
| Non-Current Liabilities | |
| Other Non-Current Liabilities | 360 |
| TOTAL | $360 |
| Total Liabilities | $653 |
| Shareholders' Equity | |
| Common Shares | 3 |
| Retained earnings | -2,591 |
| Other shareholders' equity | 3,800 |
| TOTAL | $1,322 |
| Total Liabilities And Equity | $1,975 |